Treatment of patients with multiple myeloma than 65–70 years of age and the role of maintenance therapy after transplantation stem cells
Journal Title: OncoReview - Year 2011, Vol 1, Issue 4
Abstract
Treatment of myeloma has changed significantly in the past decade as results of better understanding of disease biology, more effective treatments, and improved supportive care. Autologous stem cell transplantation (SCT) is an effective treatment for myeloma and remains a critical component in its management. Given the potential impact of therapy on stem cell collection, initial treatment decision in myeloma still depend on the patient’s transplant eligibility. The goals of initial therapy remain rapid disease control allowing for reversal of complications, as well as reduction in the risk of early death– all with minimal toxicity. The introduction of new drugs such as thalidomide, bortezomib, and lenalidomide has enabled us to achieve this goal, and combinations of these drugs have also led to unprecedented response depth. In addition, the drugs are newer being explorated as maintenance therapy following SCT. This review summarizes the current approach to the treatment of newly diagnosed myeloma in transplant-eligible patients.
Authors and Affiliations
Artur Jurczyszyn
Keywords
Related Articles
- EP ID EP53121
- DOI -
- Views 232
- Downloads 0
Off-label drug use in breast cancer therapy
Breast cancer is one of the most common malignancies across the world, including Poland. Chemotherapy plays an important part in the treatment of the disease. Most of the available chemotherapy drugs and regimens have un...
The role of granulocyte colony-stimulating factors in the prevention of neutropenia and febrile neutropenia – the current state of knowledge
Granulocyte colony-stimulating factors, introduced in the 1990s to prevent neutropenic fever, improve patients’ prognosis after myelotoxic chemotherapy. G-CSFs accelerate bone marrow recovery, shortening the duration of...
Depresja u osób z chorobą nowotworową. Rozpoznawanie i leczenie – aspekty praktyczne
Współwystępowanie depresji oraz choroby nowotworowej jest stanem częstym, choć współczynniki współistnienia obu chorób różnią się w zależności od takich czynników jak umiejscowienie nowotworu oraz faza choroby nowotworow...
Cardiooncological balance in a 75-year-old male with a hepatocellular carcinoma CS IV and a congestive heart failure NYHA III „de novo”
The case reports about a 75-years-old man without a previous medical history, in whom a heart failure NYHA III de novo was diagnosed together with persistent atrial fibrillation and hepatocellular carcinoma in clinical s...
High risk pulmonary embolism in oncology
Pulmonary embolism is a frequent complication of both cancer and the oncologic therapy. There is still discussed the subject of optimal antithrombotic prophylaxis in oncology. This article presents the patient with metas...